Classification of vitamin combination as medicament fails where therapeutic use is absent; extended limitation upheld for non-disclosure.

A fixed-dose combination of Vitamins B-1, B-6 and B-12 was held not to qualify as a medicament under Chapter 30 because Note 2(i) requires therapeutic or prophylactic use, and the material on record showed no therapeutic justification for the product. It was therefore classifiable under Heading 29.36. On limitation, non-disclosure of the product's lack of therapeutic value justified invocation of the extended period, and the reduced penalty was maintained as reasonable. The appeal failed, with classification, duty demand, limitation objection and penalty all upheld.

---

---

Issues: (i) Whether the product Aneudox-12 was classifiable as a medicament under Chapter 30 of the Central Excise Tariff Act, 1985 or under Heading 29.36. (ii) Whether the extended period of limitation was invocable and the penalty sustained.

Issue (i): Whether the product Aneudox-12 was classifiable as a medicament under Chapter 30 of the Central Excise Tariff Act, 1985 or under Heading 29.36.

Analysis: Under Note 2(i) to Chapter 30, a medicament must be a product having therapeutic or prophylactic use. The product in question was a fixed dose combination of Vitamins B-1, B-6 and B-12, and the material relied upon showed that the competent authorities had found no therapeutic justification for its use and had issued a prohibition notification. Once the product lacked therapeutic value, it could not satisfy the statutory requirement for classification as a medicament.

Conclusion: The product was not classifiable under Chapter 30 as a medicament and was correctly classified under Heading 29.36.

Issue (ii): Whether the extended period of limitation was invocable and the penalty sustained.

Analysis: The record showed that the appellants did not disclose the material fact that the product had no therapeutic value. In the circumstances, the non-disclosure justified invocation of the extended limitation period. The reduced penalty imposed by the Commissioner (Appeals) was found to be reasonable.

Conclusion: The extended period of limitation was rightly invoked and the penalty was sustained.

Final Conclusion: The appeal failed in entirety and the classification, duty demand, limitation objection, and penalty were all upheld.

Ratio Decidendi: A product can be classified as a medicament under Chapter 30 only if it has therapeutic or prophylactic use, and non-disclosure of a material fact affecting classification justifies invocation of the extended period of limitation.

---